Alcon Inc. · ALC · FY2026 Q3 · Calendar Q4 2026

Alcon holds FY outlook as new launches meet IOL competition

The supplied analysis supports a measured growth case: Alcon reported continued sales growth and maintained its full-year outlook, with product launches, premiumization and contact-lens share gains as potential drivers. That case is balanced by U.S. implantable IOL competition and execution, adoption and margin uncertainties around launches and its acquisition.

Why did ALC fall 2.3% after beating EPS estimates in FY2026 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNYSEHealthcare $35.80B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.91 Consensus $0.89
EPS surprise +2.2% Reported versus consensus
Reported revenue $2.68B Consensus $2.68B
Revenue surprise -0.2% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move -2.3% Event window
SPY move +1.4% Same window
Abnormal move -3.7% Stock minus SPY
Volume 1.8× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
ALCSPY benchmark

Ask FN2 about ALC FY2026 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, the Q3 account centers on sales growth meeting the guidance midpoint and a maintained full-year outlook. The supplied analysis also identifies the Neurotech acquisition and ENCELTO launch, FDA approvals for Vivity Pro and BRYTLY, and ongoing U.S. premium IOL competition as salient developments.

Guidance delta

Management maintained the full-year outlook, described in the supplied analysis as approximately 6% sales growth and double-digit core EPS growth. No change to guidance was reported.

Key takeaways

  • UNITY platform momentum and contact-lens share gains were highlighted as contributors to the quarter.
  • Management maintained its full-year outlook.
  • The portfolio of launches includes Vivity Pro, TruPlus, BRYTLY and ENCELTO; adoption and commercial execution remain important.
  • Competitive pressure in U.S. implantable IOLs remains a counterweight to the growth case.

Management priorities

  • Commercialize new products and expand premiumization across contact lenses and IOLs.
  • Advance the dry-eye franchise and newer retinal and ocular-health opportunities.
  • Continue the efficiency program and integrate and commercialize the Neurotech acquisition.

Follow ALC with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ALC REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q3 '23 actual $2B, None Q4 '23 actual $2B, None Q1 '24 estimate $3B Q1 '24 actual $2B, miss Q2 '24 estimate $3B Q2 '24 actual $3B, miss Q2 '25 estimate $3B Q2 '25 actual $3B, miss Q3 '25 estimate $3B Q3 '25 actual $3B, miss Q4 '25 estimate $3B Q4 '25 actual $3B, miss Q1 '26 estimate $3B Q1 '26 actual $3B, beat Q2 '26 estimate $3B Q2 '26 actual $3B, beat Q3 '26 estimate $3B Q3 '26 actual $3B, beat Q4 '26 estimate $3B Q1 '27 estimate $3B Q2 '27 estimate $3B Q3 '27 estimate $3B
Show less

Analyst Consensus ?

ConsensusHold26 ratings
Bullish1453.8%
Neutral1038.5%
Bearish27.7%

Analyst 52W Price Targets

$74.31Current
$35Low
$87.16Average
$110High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Stifel Hold HoldMaintainNov 12, 2026
Barclays Equal Weight Equal WeightMaintainNov 12, 2026
Baird Outperform OutperformMaintainNov 12, 2026
Needham Buy BuyMaintainNov 11, 2026
BTIG Buy BuyMaintainNov 11, 2026
Show 21 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $74.31. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BernsteinSusannah Ludwig$88.9$72.8 +19.6%Nov 12, 2026
NeedhamDavid Saxon$98$71.45 +31.9%Nov 2, 2026
KeyBancAnalyst unavailable$84$69.99 +13.0%Oct 27, 2026
BTIGAnalyst unavailable$74$64.14 -0.4%Oct 12, 2026
BarclaysChristopher Pasquale$70$63.19 -5.8%Oct 6, 2026
See 46 more

Track every rating change on ALC the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as…

Historical context

All ALC earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain

Latest beats and misses

Who reports next

Get the ALC recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-11-11T20:10:51.921415+00:00
  2. FN2 earnings calendar · 2026-11-11T01:23:13.633975+00:00
  3. Polygon adjusted daily market bars · 2026-11-11T20:20:45.409194+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-11T20:20:45.405479+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-11. For educational purposes only; not investment advice.